. , 75%. , 15 .
( VIII IX ), .
. VIII IX, .
, , , , .
1. 1- .
2. .
3. , , .
5. , , . :
- (, ) - ;
- - ;
- , , .
4. ( ). !
5. ( ) .
6. (). , , , ( !) . ( , ) .
7. . .
8. ( , , ). , , .
|
|
|
9. , ( ) () . ().
10. . .
11. ( ) ( ).
12. , , , , - , .
13. , B ( D, C), , .
: ( , ); 6 ; ( , , ); ; ; (, ); .
( VIII , , , ).
, . , ( , , ), - , , ( , , , ), , . VIII IX 50%.
, :
1. ( 12 50%, 24 25%). , VIII .
2. 10 / 6 . 1 1 . 12 VIII V .
3. ( VIII IX , 30 , 1 ) 6 / 3-4 . VIII 60-100 ( 80 ) 30-40 .
|
|
|
4. VIII IX 1 ( VIII 1 ) 2% . 2-3 ( , VIII 8-12 ).
VIII IX .
| VIII, | (Octapharma Nordic AB, Sweden), (Octapharma Nordic AB, Sweden), (Baxter Hyland Immuno, USA), (Baxter Hyland Immuno, USA), (Bayer, USA), (Kedrion, Italy), (Biotest Pharma Germany) |
| VIII - () | (Baxter Hyland Immuno, USA), (Bayer, USA) |
| IX, | (Octapharma Nordic AB, Sweden), (Baxter Hyland Immuno, USA), (Kedrion, Italy) |
5. (II, VII, IX, X ) , , 1 / 1%.
. . 1 20 25-40 / 3 , IX 25-40 / 2 . 1,5-2 4-5- VIII IX .
, VIII IX . 45-50 /, IX 35 /.
VIII IX , () VIII, 1 , VIII 1,5-2%, 1 IX 0,8%.
